←
Gossamer Bio377 posts
Gossamer Bio avatar

Gossamer Bio

@GossamerBio

Clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

◷ Joined December 2018▧ 261 Photos and videos
Gossamer Bio avatar
Gossamer Bio@GossamerBio·Oct 1

Last week we submitted our first New Drug Application to the FDA for seralutinib in PAH. An NDA is the formal application requesting that the FDA review a medicine to determine whether it may be approved for use in patients. #PAH #PulmonaryHypertension

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·Sep 3

A lot has happened since our last update. Productive FDA engagement, a planned fall NDA submission for seralutinib in PAH, reacquired worldwide rights, and up to $250M in financing. Energized for what’s ahead. See you at #ERS2026! #PAH

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·Sep 2

Gossamer teams up with Dr. Marc Simon of UCSF at PHA walk to raise awareness and support for the pulmonary hypertension patient community. #PHA

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·Mar 17

We were pleased to join leading experts at the PH West Utah Pulmonary Hypertension Symposium to discuss some of the latest research and clinical guidance in #PH. Thank you to the organizers and speakers for an engaging and impactful event!

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·23 Dec 2025

It’s been an incredible year for us at Gossamer Bio, and we’re excited for what’s ahead as we continue to work toward our mission: enhancing the lives of people living with #PAH and #PH-ILD. Wishing everyone a joyful and peaceful festive season. Happy holidays!

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·10 Dec 2025

Grateful to @TeamPHHope for an impactful 3rd Annual PHenomenal Hope Symposium. The focus on advancing knowledge, research, and advocacy in #PH was energizing, and we’re committed to continuing to support progress in patient-centered research.

Post attachmentPost attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·27 Nov 2025

Here at Gossamer Bio, we’re thankful for another year of working together to improve the lives of those affected by pulmonary hypertension. Happy Thanksgiving to those who celebrate!

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·25 Nov 2025

We’re excited to join the 3rd annual PHenomenal Hope Research Symposium on Dec 5 in Boston! With a focus on patient-centered innovation and care, we’re proud to support such an important event. Thank you @TeamPHHope for helping drive progress in the field.

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·20 Nov 2025

We were honored to support this year’s Right Heart Fight on Nov 8 in Oklahoma, bringing the #PH community together to raise funds & awareness. Events like this remind us why our work matters. We look forward to continuing the fight for healthier futures. #PHAwarenessMonth

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·19 Nov 2025

We were delighted to attend and support the @PFFOrg Summit, November 13-15, 2025 in Chicago – the world’s largest conference on pulmonary fibrosis and interstitial lung disease. It was a fantastic opportunity to learn, connect and collaborate. Thank you to the PFF for organizing!

Post attachment
Gossamer Bio avatar
Gossamer Bio@GossamerBio·13 Nov 2025

A key highlight of #PHAwarenessMonth so far was the opportunity to connect with many of the leading patient organizations at the Annual Pulmonary Hypertension European Conference (#APHEC). Thank you for a great meeting, PHA Europe!

Post attachment